REG - Ondine Biomedical - Share Issuance for ICU Study Enrollment Completion

Ondine BiomedicalAnnouncement

Tue 17:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250722:nRSV1296Sa&default-theme=true

RNS Number : 1296S  Ondine Biomedical Inc.  22 July 2025

22 July 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Milestone-based Share Issuance Following Completion of Steriwave ICU Study
Enrollment

Further to the announcement on 21 July 2025, Ondine Biomedical Inc. (AIM:
OBI), a Canadian life sciences company pioneering light-activated,
non-antibiotic infection prevention therapies,  announces the issuance of
800,457 common shares of no par value each in the capital of the Company
("Shares") to the Royal Columbian Hospital Foundation following the successful
enrollment of the final patient in the world's first ICU nasal
photodisinfection trial using Steriwave(®).

This share issuance represents the third milestone payment, equivalent to 25%
of the C$855,000 total pilot study cost, as stipulated in the original
clinical trial agreement. The new Shares have been issued at a price of 14.50
pence per Share, reflecting the closing market price of the Company's Shares
on the London Stock Exchange (AIM) two business days preceding this milestone.
Application will be made for admission of the new Shares to trading on AIM
("Admission").

The trial, conducted at Royal Columbian Hospital (RCH)-a major tertiary and
trauma centre in British Columbia-marks the first-ever use of Steriwave nasal
photodisinfection in a critically ill ICU patient population. With ICU
hospital-acquired infection (HAI) rates reaching 12-13% [ 1  (#_edn1) ] and
respiratory pathogens accounting for over 62% of ICU-acquired infections [ 2 
(#_edn2) ], the study explored the feasibility, workflow integration, and
patient acceptance of Steriwave as a nasal decolonization tool to support
infection prevention in intensive care settings.

Carolyn Cross, CEO of Ondine Biomedical, commented:

"We are grateful to the RCH Foundation's Advancing Innovation in Medicine
(AIM) for its support of our efforts to bring the benefits of a broad spectrum
nasal decolonization protection to critical care patients. Being able to
finance this pioneering trial through equity has enabled us to accelerate the
development of the important and sizeable ICU market for Steriwave."

Admission of the 800,457 new Shares will take place on or around 8:00 a.m. on
28 July 2025. The new Shares, when issued, will be fully paid and will rank
pari passu in all respects with the existing Shares, including the right to
receive all dividends and other distributions declared after the date of
issue.

Following Admission, the Company's issued share capital will consist of
444,233,631 Shares, each carrying one voting right per share. The Company does
not hold any Shares in treasury. Therefore, the total number of voting rights
in the Company will be 444,233,631, which may be used by shareholders to
determine whether they are required to notify their interest in, or a change
to their interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com
 Carolyn Cross, CEO                                          +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Advisor)
 James Steel, Dr. Chris Golden                               +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                            +44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

(#_ednref1) [ 1 ] European Centre for Disease Prevention and Control (ECDC).
Healthcare‑associated infections acquired in intensive care units. Annual
Epidemiological Report for 2020. Stockholm: ECDC; 15 March 2024. (link
(https://www.ecdc.europa.eu/en/publications-data/healthcare-associated-infections-acquired-intensive-care-units-annual)
)

(#_ednref2) [ 2 ] Vincent JL, Rello J, Marshall J, et al. International
Study of the Prevalence and Outcomes of Infection in Intensive Care Units
(EPIC II). JAMA. 2009;302(21):2323‑2329. (link
(https://jamanetwork.com/journals/jama/fullarticle/184963) )

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFZGZNVZNGKZM